Asklepios BioPharmaceutical
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders and other rare diseases. It offers proprietary AAV technology, manufacturing capabilities, and a robust pipeline of in-house clinical programs for clients in the medical biopharmaceutical industry. Its pipeline includes clinical-stage programs in Pompe disease and congestive heart failure and a diverse preclinical portfolio of therapeutics targeting neuromuscular, CNS, and other diseases, as well as out-licensed clinical indications for hemophilia and Duchenne muscular dystrophy. The company’s gene therapy platform includes Pro10, an industry-leading proprietary cell line manufacturing process, and an extensive AAV capsid, and promoter library. Asklepios BioPharmaceutical was founded in 2001 and is headquartered in Research Triangle Park, North Carolina.
Tech Stack (2 technologies)
Frequently Asked Questions
What technologies does Asklepios BioPharmaceutical use?+
Asklepios BioPharmaceutical uses 2 technologies including HSTS, Nginx.
What industry is Asklepios BioPharmaceutical in?+
Asklepios BioPharmaceutical operates in the Biopharma industry.
Where is Asklepios BioPharmaceutical based?+
Asklepios BioPharmaceutical is headquartered in United States.
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026